Next Article in Journal
Probiotics in Intestinal Mucosal Healing: A New Therapy or an Old Friend?
Next Article in Special Issue
In Vivo Imaging of Rat Vascularity with FDG-Labeled Erythrocytes
Previous Article in Journal
RIG-I Deficiency Promotes Obesity-Induced Insulin Resistance
Previous Article in Special Issue
Thin Layer-Protected Gold Nanoparticles for Targeted Multimodal Imaging with Photoacoustic and CT
Review

Positron Emission Tomography in Animal Models of Alzheimer’s Disease Amyloidosis: Translational Implications

by 1,2
1
Institute for Biomedical Engineering, ETH & University of Zurich, 8093 Zurich, Switzerland
2
Institute for Regenerative Medicine, University of Zurich, 8952 Zurich, Switzerland
Academic Editor: Xuyi Yue
Pharmaceuticals 2021, 14(11), 1179; https://doi.org/10.3390/ph14111179
Received: 18 October 2021 / Revised: 13 November 2021 / Accepted: 15 November 2021 / Published: 18 November 2021
Animal models of Alzheimer’s disease amyloidosis that recapitulate cerebral amyloid-beta pathology have been widely used in preclinical research and have greatly enabled the mechanistic understanding of Alzheimer’s disease and the development of therapeutics. Comprehensive deep phenotyping of the pathophysiological and biochemical features in these animal models is essential. Recent advances in positron emission tomography have allowed the non-invasive visualization of the alterations in the brain of animal models and in patients with Alzheimer’s disease. These tools have facilitated our understanding of disease mechanisms and provided longitudinal monitoring of treatment effects in animal models of Alzheimer’s disease amyloidosis. In this review, we focus on recent positron emission tomography studies of cerebral amyloid-beta accumulation, hypoglucose metabolism, synaptic and neurotransmitter receptor deficits (cholinergic and glutamatergic system), blood–brain barrier impairment, and neuroinflammation (microgliosis and astrocytosis) in animal models of Alzheimer’s disease amyloidosis. We further propose the emerging targets and tracers for reflecting the pathophysiological changes and discuss outstanding challenges in disease animal models and future outlook in the on-chip characterization of imaging biomarkers towards clinical translation. View Full-Text
Keywords: Alzheimer’s disease; amyloid-beta; animal model; astrocyte; blood–brain barrier; imaging; metabolism; microglia; neuroinflammation; neurotransmitter receptors; positron emission tomography; synaptic density Alzheimer’s disease; amyloid-beta; animal model; astrocyte; blood–brain barrier; imaging; metabolism; microglia; neuroinflammation; neurotransmitter receptors; positron emission tomography; synaptic density
Show Figures

Figure 1

MDPI and ACS Style

Ni, R. Positron Emission Tomography in Animal Models of Alzheimer’s Disease Amyloidosis: Translational Implications. Pharmaceuticals 2021, 14, 1179. https://doi.org/10.3390/ph14111179

AMA Style

Ni R. Positron Emission Tomography in Animal Models of Alzheimer’s Disease Amyloidosis: Translational Implications. Pharmaceuticals. 2021; 14(11):1179. https://doi.org/10.3390/ph14111179

Chicago/Turabian Style

Ni, Ruiqing. 2021. "Positron Emission Tomography in Animal Models of Alzheimer’s Disease Amyloidosis: Translational Implications" Pharmaceuticals 14, no. 11: 1179. https://doi.org/10.3390/ph14111179

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop